Evidence map›Paper›PMID 35209087›Full record

ArticleMolecules (Basel, Switzerland)2022

Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties.

Margherita Mastromarino, Mauro Niso, Carmen Abate, Ewgenij Proschak, Mariam Dubiel, Holger Stark, Marián Castro, Enza Lacivita, Marcello Leopoldo

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Margherita MastromarinoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.
Mauro NisoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.
Carmen AbateDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-9292-884X
Ewgenij ProschakInstitute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
Mariam DubielInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstrasse 1, 40225 Duesseldorf, Germany.
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstrasse 1, 40225 Duesseldorf, Germany.ORCID 0000-0003-3336-1710
Marián CastroCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Avda de Barcelona s/n, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-4732-1966
Enza LacivitaDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.ORCID 0000-0003-2443-1174
Marcello LeopoldoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-8401-2815
University of Bari Aldo Moro · ITHeinrich Heine University Düsseldorf · DEGoethe University Frankfurt · DEUniversidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-chain arylpiperazine scaffold is a versatile template to design central nervous system (CNS) drugs that target serotonin and dopamine receptors. Here we describe the synthesis and biological evaluation of ten new arylpiperazine derivatives designed to obtain an affinity profile at serotonin 5-HT

Indexed as

Chemistry Techniques, SyntheticDrug DesignCell LineCell SurvivalDopamine D2 Receptor AntagonistsHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureNeuroprotective AgentsReceptors, DopamineReceptors, SerotoninStructure-Activity RelationshipDopamine D2 Receptor AntagonistsLigandsNeuroprotective AgentsReceptors, DopamineReceptors, Serotonin5-HT1A5-HT2A5-HT7arylpiperazineD2dopamineoxidative stressserotonin

Identifiers

PMID35209087
PMCPMC8877291
OpenAlexW4213115910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.